Phinney Lab Publications

The following articles were published by Don Phinney, his lab members and his collaborators.

Lai WT, Krishnappa V, Phinney DG. Fibroblast growth factor 2 (Fgf2) inhibits differentiation of mesenchymal stem cells by inducing Twist2 and Spry4, blocking extracellular regulated kinase activation, and altering Fgf receptor expression levels. Stem Cells 2011; 29:1102-1111.

Russell KC, Lacey MR, Gilliam JK, Tucker HA, Phinney DG, O’Connor KC. Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency. Biotechnol Bioeng. 2011; 108:2716-2726.

Phinney DG. Twist, epithelial-to-mesenchymal transition, and stem cells. Stem Cells 2011; 29:3-4.

Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem cell therapy as an emerging paradigm for stroke (STEPS) II.  Stroke 2011; 42:825-829.

Adult Stem Cells: Biology and Methods of Analysis (2011). Edited by Phinney DG, Humana Press, New York, N.Y., USA

Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, Simmons PJ, Senesbe L, Keating A. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12:576-578.

Isakova IA, Dufour J, Lanclos C, Bruhn J, Phinney DG. Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Exp. Hematol. 2010; 38:957-967.

Barrilleaux B, Fischer-Valuck BW, Gilliam JK, Phinney DG, O’Connor KC. Activation of CD74 inhibits migration of human mesenchymal stem cells. In Vitro Cell Dev Biol Anim. 2010; March 3 [Epub ahead of print].

Russell KC, Phinney DG, Lacey MR, Barrilleaux BL, Meyertholen KE, O’Connor K C. In vitro high-capacity assay to quantify the clonal heterogeneity in tri-lineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010; 28:788-798.

Barrilleaux BL, Phinney DG, Fischer-Valuck BW, Russell KC, Wang G, Prockop DJ, O’Connor KC. Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells. Tissue Eng. Part A 2009; 15:2335-2346.

Phinney DG. A SAGE view of mesenchymal stem cells. Int. J. Stem Cells 2009; 2:1-10.

Phinney DG. Isolation of mesenchymal stem cells from murine bone marrow by immunodepletion. Methods Mol. Biol. 2008; 449:171-186.

Phinney DG. (2008) Marrow Stem Cells, pp. 95-122 in Advances in Tissue Engineering. Edited by J. Polak, S. Mantalaris, and S. Harding, Imperial College Press, London.

Ortiz LA, DuTreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the anti-inflammatory and anti-fibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. USA 2007; 104:11002-11007.

Phinney DG. Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle 2007; 6:2884-2889.

Phinney DG, Prockop DJ. The state of trans-differentiation and modes of tissue repair: current views. Stem Cells 2007; 25:2896-2902.

Isakova IA, Baker K, Dufour J, Gaupp D, Phinney DG. Dose and age-related effects on MSCs engraftment levels and anatomical distribution in the CNS of non-human primates: Identification of novel MSC subpopulations that respond to guidance cues in brain. Stem Cells 2007; 25:3261-3270.